Showing 4341-4350 of 5910 results for "".
- Alcon Completes Acquisition of Aerie Pharmaceuticalshttps://modernod.com/news/alcon-completes-acquisition-of-aerie-pharmaceuticals/2481258/Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals. In August, Alcon announced its was acquiring Aerie for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s closing price prior to the deal. The deal bolsters Alcon's
- Study: Form of AMD Strongly Associated With Cardiovascular Diseasehttps://modernod.com/news/study-blinding-eye-disease-strongly-associated-with-serious-forms-of-cardiovascular-disease/2481254/Patients with a specific form of age-related macular degeneration (AMD) are also highly likely to have either underlying heart damage from heart failure and heart attacks, or advanced heart valve disease, or carotid artery disease associated with certain types of strokes, according to a new study
- Sightpath Medical Acquires Accusite Surgicalhttps://modernod.com/news/sightpath-medical-acquires-accusite-surgical/2481253/Sightpath Medical announced that it has acquired Accusite Surgical, a cataract surgery equipment outsourcing company. Terms of the deal were not disclosed. Founded in 1991, Sightpath Medical delivers custom access to ophthalmic equipment, instruments, and services. Through its patented
- Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date for Pegcetacoplan for GAhttps://modernod.com/news/apellis-announces-fda-acceptance-of-nda-amendment-and-new-pdufa-date-of-february-26-2023-for-pegcetacoplan-for-ga/2481252/Apellis Pharmaceuticals announced that the FDA has accepted Apellis’ unsolicited major amendment to the new drug application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The updated Prescription D
- GenSight Biologics Announces Publication of Results of Lumevoq REFLECT Pivotal Clinical Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-of-lumevoq-reflect-pivotal-clinical-trial/2481250/GenSight Biologics announced that the neurology journal BRAIN has published efficacy and safety findings at 1.5-year post-treatment in ND4-LHON patients treated with lenadogene nolparvovec (Lumevoq) from the REFLECT pivotal clinical trial. The REF
- ViaLase Makes Several Appointments to its Executive Teamhttps://modernod.com/news/vialase-makes-several-appointments-to-its-executive-team/2481244/ViaLase announced the appointments of Tom Frinzi as Executive Chairman of the Board; Richard Lewis, MD, as Chief Medical Officer; Shawn O'Neil as Chief Commercial Officer; and Brendan O'Herlihy as Vice President, Global Commercial Operations. The executives w
- EssilorLuxottica Supports New WSPOS Independent Medical Education Program on Myopia Managementhttps://modernod.com/news/essilorluxottica-supports-new-wspos-independent-medical-education-program-on-myopia-management/2481243/EssilorLuxottica announced it is supporting the World Society of Paediatric Ophthalmology and Strabismus (WSPOS) independent medical education program on myopia management, as a gold level supporter, which will be launched on November 19 and 20, at 2-4pm GMT. The key goals of this progr
- Nidek Launches the NT-1p Non-Contact Tono/Pachymeterhttps://modernod.com/news/nidek-launches-the-nt-1p-non-contact-tonopachymeter/2481241/Nidek announced the launch of the NT-1p Non-Contact Tono/Pachymeter. The NT-1p is an innovative device that fully automates reliable non-contact tonometry and pachymetry. By placing the chin on the chinrest, the NT-1p automatically detects the position of the eyes and begins measurement without p
- Harrow Launches Atropine.comhttps://modernod.com/news/harrow-launches-atropinecom/2481236/Harrow announced the launch of atropine.com, an ordering and marketing portal designed specifically for prescribers interested in compounded atropine formulations. All atropine.com, prescriptions will be dispensed through Harrow’s wholly owned
- Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-announces-positive-results-in-safety-durability-and-biologic-effect-in-oasis-phase-12a-clinical-trial-of-suprachoroidal-cls-ax-in-wet-amd-patients/2481234/Clearside Biomedical announced positive results from its OASIS phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in wet age-related macular degeneration (AMD) patients. Trial results include f